ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,480Medicare Part D Prescriptions Filled, Including Refills

Rank: 13 out of 122

$557K Total Retail Price of All Prescriptions

Rank: 12 out of 122

258 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
43% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Vermont
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 258 patients filled at least one prescription for a schedule two drug, compared to an average of 10%.

Schedule Three
Controlled Substances

9% of this provider’s 258 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 7,642 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$66 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

33 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Vermont
FUROSEMIDE 315 310 1 5
SIMVASTATIN 299 286 2 1
OMEPRAZOLE 299 273 2 3
LISINOPRIL 275 241 4 2
HYDROCHLOROTHIAZIDE 247 233 5 6
ATENOLOL 216 209 6 10
AMLODIPINE BESYLATE 192 169 7 7
LEVOTHYROXINE SODIUM 176 175 8 4
PANTOPRAZOLE SODIUM 169 169 9 23
LOSARTAN POTASSIUM 168 168 10 17
ATORVASTATIN CALCIUM 158 145 11 13
METOPROLOL SUCCINATE 138 138 12 11
EVISTA 133 133 13 102
PRAVASTATIN SODIUM 126 122 14 27
ALENDRONATE SODIUM 118 118 15 35
TRAMADOL HCL 113 90 16 20
POTASSIUM CHLORIDE 107 90 17 22
ZOLPIDEM TARTRATE 101 81 18 19
DIOVAN 94 78 19 40
CRESTOR 92 88 20 37
METOPROLOL TARTRATE 90 90 21 8
GABAPENTIN 89 69 22 12
METFORMIN HCL ER 83 75 23 84
FLUTICASONE PROPIONATE 82 74 24 49
GLIMEPIRIDE 82 79 24 51
LANTUS 81 79 26 36
PREDNISONE 78 69 27 24
VENLAFAXINE HCL ER 77 61 28 54
SERTRALINE HCL 75 62 29 18
CITALOPRAM HBR 75 67 29 15
CLOPIDOGREL 71 71 31 45
SPIRONOLACTONE 70 70 32 63
CELEBREX 70 54 32 52
RANITIDINE HCL 69 50 34 39
ZETIA 67 52 35 84
NEXIUM 64 46 36 32
FINASTERIDE 64 60 36 76
FLUOXETINE HCL 63 53 38 38
METFORMIN HCL 63 61 38 14
TAMSULOSIN HCL 62 62 40 26
PLAVIX 61 60 41 81
NABUMETONE 61 53 41 124
DILTIAZEM ER 60 60 43 132
LEVOFLOXACIN 57 43 44 80
CLONIDINE HCL 55 55 45 160
ALLOPURINOL 55 55 45 33
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 5, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.